MAP3K15 and diabetes mellitus: Nonetheless, the effect sizes for diabetes risk, HbA1c, and metformin use in hemizygous MAP3K15 PTV carriers compared to heterozygous carriers demonstrate that the protective effect of MAP3K15 loss is dose dependent.